Domain III of the envelope protein as a dengue vaccine target
- 1 February 2010
- journal article
- review article
- Published by Informa UK Limited in Expert Review of Vaccines
- Vol. 9 (2), 137-147
- https://doi.org/10.1586/erv.09.139
Abstract
A dengue vaccine should induce long-lasting, simultaneous protection to the four dengue viruses while avoiding the immune enhancement of viral infection. Domain III of the dengue envelope protein has been implicated in receptor binding, and is also the target of specific neutralizing antibodies. Domain III has emerged as a promising region for a subunit vaccine candidate. Here, we review the current state of knowledge on vaccine candidates based on domain III. Due to the results obtained concerning the immune response and protection in mice and monkeys, particular attention is paid to the chimeric protein domain III fused to p64k of Neisseria meningitidis.Keywords
This publication has 92 references indexed in Scilit:
- Passage of Dengue Virus Type 4 Vaccine Candidates in Fetal Rhesus Lung Cells Selects Heparin-Sensitive Variants That Result in Loss of Infectivity and Immunogenicity in Rhesus MacaquesJournal of Virology, 2009
- Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibodyVirology, 2009
- Characterization of Dengue Virus Complex-Specific Neutralizing Epitopes on Envelope Protein Domain III of Dengue 2 VirusJournal of Virology, 2008
- Pediatric Measles Vaccine Expressing a Dengue Antigen Induces Durable Serotype-specific Neutralizing Antibodies to Dengue VirusPLoS Neglected Tropical Diseases, 2007
- DengueThe Lancet, 2007
- Recent Advances in Deciphering Viral and Host Determinants of Dengue Virus Replication and PathogenesisJournal of Virology, 2006
- Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever‐dengue shock syndrome (DHF/DSS)Immunology & Cell Biology, 2006
- Differential Enhancement of Dengue Virus Immune Complex Infectivity Mediated by Signaling-Competent and Signaling-Incompetent Human FcγRIA (CD64) or FcγRIIA (CD32)Journal of Virology, 2006
- Characterization of Antibody Responses to Combinations of a Dengue Virus Type 2 DNA Vaccine and Two Dengue Virus Type 2 Protein Vaccines in Rhesus MacaquesJournal of Virology, 2006
- Dengue Viremia Titer, Antibody Response Pattern, and Virus Serotype Correlate with Disease SeverityThe Journal of Infectious Diseases, 2000